Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsTaro pharmaceuticals

    Taro Pharmaceuticals

    Jump to

    • Sun Pharma Q3 profit dragged by slowdown in US & India sales

      US generics business that accounts for nearly half of Sun Pharma sales grew at a moderate pace of 4 percent USD 507 million in the third quarter.

    • US files first charges in generic drug price-fixing probe

      The two men are in talks with the government about a plea agreement, according to a source close to the negotiations who was not authorized to discuss the matter.

    • Taro recalls 17,100 kits of dandruff care kits in US

      "Taro Pharmaceuticals USA Inc is recalling the drug because of it being subpotent drug: out of specification assay values on stability for the active ingredient, zinc pyrithione," the latest Enforcement Report of health regulator USFDA has said.

    • Sun Pharma gains 1% on Canadian co's acquisition by Taro

      US subsidiary Taro Pharmaceuticals has acquired Canada's Zalicus Pharmaceuticals, says a media report.

    • Suven Life up 5%; Taro to sell co's anti-lice lotion in US

      Suven Life Sciences today has granted an exclusive license and right to distribute and market its Malathion Lotion USP 0.5 percent w/v with US patent # 8,138,366 and ANDA 091559 in USA, Canada and Mexico to Taro Pharmaceuticals North America.

    • Taro Q1 net profit falls 6.5% to USD 58.8 mn

      Kal Sundaram, Taro‘s CEO said, “The revenue decline is principally due to a net charge taken to meet contractual obligations associated with price adjustments made in the current quarter, the benefit of which should be realized in future periods. Excluding the one-time charge, Q1 sales would have increased over 10 percent versus the prior year."

    • Taro recalls skin treatment cream from US, Puerto Rico mkts

      Taro Pharmaceuticals, the Israel- based subsidiary of Sun Pharmaceuticals, has recalled nearly 40,000 tubes of Fluorouracil topical cream, used to treat various skin conditions, from the American market.

    • Sun Pharma to acquire Taro, to pay $367m for 33.5% stake

      Drug firm Sun Pharma today said it has proposed to fully acquire Taro Pharmaceuticals with an offer to purchase all the outstanding shares of the Israeli firm that would entail an outgo of USD 367.5 million (over Rs 1,810 crore).

    • Taro sues Suven Life Sciences for patent infringement

      Taro Pharmaceuticals has sued Hyderabad-based Suven Life Sciences to prevent it from launching a generic version of Ovide malathion lotion, which is used to kill head lice.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347